Conference Coverage

Comorbid spondyloarthritis and fibromyalgia lower response to TNF inhibitors


 

REPORTING FROM RHEUMATOLOGY 2018


The BSRBR-AS is funded by the British Society for Rheumatology, which in turn receives funding from AbbVie, Pfizer, and UCB. Dr. Macfarlane did not provide any disclosures but has previously acknowledged receiving an honorarium from Pfizer and research funding from AbbVie and Pfizer for the Scotland Registry for Ankylosing Spondylitis study.

SOURCE: Macfarlane GJ et al. Rheumatology. 2018;57(Suppl. 3):key075.183.

Pages

Recommended Reading

TNFi response evaluations may conflict when fibromyalgia, axial SpA coexist
MDedge Internal Medicine
FDA approves infliximab biosimilar Ixifi for all of Remicade’s indications
MDedge Internal Medicine
TNF inhibitors curb spinal x-ray progression in ankylosing spondylitis
MDedge Internal Medicine
Role of musculoskeletal ultrasound expands in rheumatic diseases
MDedge Internal Medicine
Arthritis limits physical activity the most in the South
MDedge Internal Medicine
FDA approves certolizumab label update for pregnancy, breastfeeding
MDedge Internal Medicine
Axial SpA disease activity remains mostly stable throughout pregnancy
MDedge Internal Medicine
TB in 2017: Good news and bad news
MDedge Internal Medicine
MACE risk similar across arthritis subtypes
MDedge Internal Medicine
Physical therapy, exercise still relevant for ankylosing spondylitis
MDedge Internal Medicine